PV Reporter

09/08/2026

“Can we engineer disease trajectories in MPNs?” 🎯

That question from Dr. Alessandro Lucchesi posted on LinkedIn stopped me.

For years, much of the MPN treatment conversation has focused on controlling blood counts, reducing spleen size, easing symptoms, and lowering immediate risks. Those goals remain essential. But the discussion is becoming more ambitious:

Can we intervene earlier, match the right treatment to the right patient, and actually change where the disease is headed?

This will be the central focus of RiseMPN 2026, taking place November 6–7 in Rome, Italy.

We now have more tools in the MPN arsenal. JAK inhibitors, interferons, hepcidin-axis treatments, epigenetic therapies, p53/MDM2 strategies, activin ligand traps, and other investigational approaches are expanding the possibilities.

The next challenge is determining:

• Which treatments or combinations can truly modify disease biology?
• Which patients are most likely to benefit?
• When is the best time to intervene?
• Can we delay or prevent progression rather than responding after it occurs?

Having more treatments does not automatically mean we are changing the natural history of an MPN. That still has to be proven through strong clinical research. But I am impressed that the conversation is moving beyond symptom control and asking a much bigger question: Can we deliberately change the trajectory of these diseases?

That is the direction patients have been waiting for.

Thank you to Dr. Alessandro Lucchesi for sharing this thoughtful perspective and helping move this important discussion forward. I will be watching RiseMPN 2026 closely and sharing meaningful developments with the MPN community.

Learn more: https://risempn.org

Can we engineer disease trajectories in MPNs? Rome, 6–7 November 2026.

09/03/2026

I’m honored to share that Hemostasis Today has selected and featured my recent PV Reporter article covering the FDA approval of MIMRYLO™ (rusfertide) for adults with polycythemia vera.

This recognition means a great deal to me. For more than 13 years, my goal has been to provide the MPN community with clear, independent, and patient-focused reporting that helps people have better conversations with their healthcare teams.

Thank you to Hemostasis Today for recognizing this work and helping this important treatment news reach a wider audience.

09/02/2026

🩸 September is Blood Cancer Awareness Month.

This cartoon shows red blood cells “gone wild,” a playful way to highlight a serious condition: polycythemia vera (PV).

In PV, the bone marrow produces too many red blood cells and sometimes platelets and white blood cells. This can thicken the blood while raising the risk of clots, strokes, or other dangerous complications.

👉 Here is an informative article on Blood Cancer Awareness Month for MPNs and more trusted resources:

https://pvreporter.com/september-blood-cancer-awareness-month-mpns/

Feel free to share this post with your network.
Like and follow PV Reporter for more resources and updates on MPNs.

09/01/2026

An exciting new chapter in polycythemia vera treatment begins.

The FDA has approved MIMRYLO™ (rusfertide), the first hepcidin mimetic for erythrocytosis in adults with PV.

For patients struggling with uncontrolled hematocrit and repeated phlebotomies, this approval brings a completely new treatment approach.

Our detailed report explains how MIMRYLO works, the VERIFY trial results, safety information, and questions for patients to ask their hematologists.

Check it out and feel free to share:

FDA approved Mimrylo (rusfertide) on Aug. 28, 2026, for erythrocytosis in adults with PV. Questions to ask your MPN specialist, trial results, side effects, etc.

08/31/2026

🗞 Great news for ET community!

FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia. We will have more details coming soon.

08/30/2026

Ever wondered how doctors actually see inside you? This side-by-side comparison shows the incredible difference between X-ray, CT, and MRI scans. I thought this was a cool depiction. Which one did you have recently?

08/29/2026

📰Big news for the PV community: the FDA has approved MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic therapy for adults with polycythemia vera!

A detailed article on what this means for patients and the PV treatment landscape is coming soon! Stay tuned on pvreporter.com for the latest MPN news updates.

08/28/2026

Blast from the Past: Celebrating PV Reporter’s 13-year anniversary since launching in Aug. 2013! 🎉

What began as a simple idea has grown into a trusted hub for MPN research, education, patient stories, and connection. PV Reporter has become my life’s passion, and every article, resource, and interview has been part of that journey.

Thank you to our loyal readers, supporters, and amazing sponsors for helping us empower the MPN community and reach the newly diagnosed. 💙

Here’s to another year of service and the joy of helping others. https://www.pvreporter.com/

08/25/2026

Six-Month Ruxolitinib Response May Predict Long-Term PV Outcomes

A new prognostic model uses 6-month ruxolitinib response to identify patients with polycythaemia vera at risk of poorer long-term outcomes.